Cara Therapeutics Inc (CARA)
0.444
-0.24
(-34.66%)
USD |
NASDAQ |
Jun 13, 16:00
0.4451
0.00 (0.00%)
After-Hours: 20:00
Cara Therapeutics Gross Profit (TTM): 12.73M for March 31, 2024
Gross Profit (TTM) Chart
Historical Gross Profit (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 12.73M |
| December 31, 2023 | 14.79M |
| September 30, 2023 | 13.53M |
| June 30, 2023 | 17.98M |
| March 31, 2023 | 35.47M |
| Date | Value |
|---|---|
| December 31, 2022 | 34.60M |
| September 30, 2022 | 34.29M |
| June 30, 2022 | 46.80M |
| March 31, 2022 | 23.80M |
| December 31, 2021 | 23.03M |
Gross Profit Definition
Gross profit is the difference between sales and the cost of goods sold. Revenues (aka Sales) less Cost of Goods Sold (COGS) is a company's gross profit. For many companies, cost of goods sold is a substantial portion of expenses.
Gross Profit (TTM) Range, Past 5 Years
12.73M
Minimum
Mar 2024
46.80M
Maximum
Jun 2022
25.70M
Average
23.42M
Median
Gross Profit (TTM) Benchmarks
| Nektar Therapeutics | 54.92M |
| Stereotaxis Inc | 14.95M |
| Verastem Inc | -- |
| Ocugen Inc | -- |
| Voyager Therapeutics Inc | -- |